Canada’s antirheumatic drugs market was evaluated at US$0.73 billion for the year 2020, growing at a CAGR of 2.18% reaching the market size of US$0.84 billion by the year 2027.
The need for antirheumatic medications in Canada is mostly driven by the country's ageing population. Statistics Canada reports that there are 5.9 million Canadian senior citizens compared to 5.8 million Canadians who are 14 and under. According to the data provided by the Government of Canada, almost one in seven Canadians was above 65 in 2012, which is projected to rise to nearly one in four by 2030. Since the prevalence of diseases causing chronic back pain and arthritis is more across this age group, the growing geriatric population in Canada will continue to drive the growth of the antirheumatic drugs market in the country throughout the forecast period.
Market players are continuously engaged in getting approval for their drugs from the Canadian Health Ministry to launch new antirheumatic drugs in the country and capture a larger market share. For example, recently, a research-based global biopharmaceutical company AbbVie got approval for its RINVOQ® from Health Canada. This medicine is used to treat moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate (MTX). As such, the market for antirheumatic drugs in Canada will continue to grow substantially during the forecast period. The availability of over-the-counter (OTC) drugs to treat rheumatic diseases further boosts the antirheumatic drugs market in Canada.
Canadian antirheumatic drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis, rheumatoid arthritis, gout, lupus, and others. By type of molecule, the Canadian Antirheumatic Drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).
The rheumatoid arthritis sector is predicted to hold a significant market share depending on the type of disease. The industry for rheumatoid arthritis treatment is fueled by the rising prevalence of arthritis and associated joint issues. In addition, the development of rheumatoid arthritis is attributed to a change toward an unhealthy lifestyle, an increase in metabolic diseases and age, a family history of joint disorders, and an increase in obesity. Furthermore, improvements in biosimilar and innovative biologics are anticipated to open up new business prospects in the sector.
Due to the rise in the number of specialist hospitals needed to treat the medical condition, the prescription-based drug segment held the biggest share of the market by sales channel. Additionally, due to increased awareness of the rheumatoid arthritis treatment choices, the over-the-counter medicine sector is anticipated to grow at the quickest rate during the projection period. Another important element driving the expansion of the anti-rheumatics business is the simple accessibility of over-the-counter NSAIDs.
Recent Developments and expansions
In November 2019, the Food and Drugs Administration granted approval for Pfizer's biosimilar, abriladaTM, to treat several inflammatory conditions, notably rheumatoid arthritis.
In order to develop, produce, and commercialize Xcimzane, a preclinical monoclonal antibody that is indicated to be a biosimilar of CIMZIA for the treatment of rheumatoid arthritis, Xbrane Biopharma AB and Biogen Inc. inked commercialization and license agreement in February 2022.
The FDA authorized Hulio, a biosimilar to Humira in 2020, according to a statement from Mylan (adalimumab, AbbVie). It is a TNF inhibitor used to treat people with rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, adult Ulcerative colitis, crohn's disease, and plaque psoriasis, among other conditions.
Canada Anti-Rheumatic Drug Market Scope
| Report Metric | Details |
|---|---|
| Total Market Size in 2020 | USD 0.73 billion |
| Total Market Size in 2027 | USD 0.84 billion |
| Forecast Unit | Billion |
| Growth Rate | 2.18% |
| Study Period | 2015 to 2027 |
| Historical Data | 2015 to 2018 |
| Base Year | 2019 |
| Forecast Period | 2020 – 2027 |
| Segmentation | Type of Disease, Type of Molecule, Sales Channel |
| Companies |
|
| Customization Scope | 15% Free Customization included with purchase — Request Custom Breakdown → |
| Sample & Data Access | PDF Sample, Excel Databook & Analyst Briefing — Download Free Sample → |
Market Segmentation
Segments
- Type of Disease
- Type of Molecule
- Sales Channel
Table of Contents
1. Introduction
1.1. Market Overview
1.2. COVID-19 Impact
1.3. Market Definition
1.4. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Canada Antirheumatic Drugs Market Analysis, By Type of Disease
5.1. Introduction
5.2. Osteoarthritis
5.3. Rheumatoid Arthritis
5.4. Gout
5.5. Lupus
5.6. Others
6. Canada Antirheumatic Drugs Market Analysis, By Type of Molecule
6.1. Introduction
6.2. Pharmaceuticals
6.3. Biopharmaceuticals
7. Canada Antirheumatic Drugs Market Analysis, By Sales Channel
7.1. Introduction
7.2. Prescription
7.3. Over-The-Counter (OTC)
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles
9.1. AbbVie Inc.
9.2. Pfizer Inc.
9.3. sanofi-aventis Canada Inc.
9.4. Amgen Inc.
Frequently asked questions
What is the projected market valuation and growth trajectory for the Canada Anti-Rheumatic Drug Market from 2022 to 2027?
The Canada Anti-Rheumatic Drug Market was valued at US$0.73 billion in 2020 and is projected to reach US$0.84 billion by 2027. This growth represents a Compound Annual Growth Rate (CAGR) of 2.18% over the forecast period, indicating a steady expansion driven by various market factors.
What are the primary demographic and market factors driving the growth of the Canadian Anti-Rheumatic Drug Market?
The Canada Anti-Rheumatic Drug Market's growth is primarily driven by Canada's ageing population, with seniors outnumbering youth, as the prevalence of chronic back pain and arthritis is higher in this demographic. Additionally, continuous new drug approvals from Health Canada, such as AbbVie's RINVOQ®, and the availability of over-the-counter (OTC) drugs further boost market expansion.
How is the Canadian Anti-Rheumatic Drug Market segmented, and which disease type holds a significant market share?
The Canadian Antirheumatic Drugs market is segmented by type of disease (osteoarthritis, rheumatoid arthritis, gout, lupus, others), type of molecule (pharmaceuticals, biopharmaceuticals), and sales channel (prescription, OTC). The rheumatoid arthritis sector is predicted to hold a significant market share due to its rising prevalence, linked to factors like unhealthy lifestyles, metabolic diseases, age, and obesity.
What are the key trends observed in sales channels for anti-rheumatic drugs in Canada?
By sales channel, the prescription-based drug segment currently holds the biggest market share, attributed to the rise in specialist hospitals for medical conditions. However, the over-the-counter (OTC) medicine sector is anticipated to grow at the quickest rate during the forecast period, driven by increased awareness of rheumatoid arthritis treatment options.
How are new drug approvals, such as RINVOQ®, influencing the competitive landscape and market opportunities in Canada?
New drug approvals from Health Canada, exemplified by AbbVie's RINVOQ® for moderate to severe active rheumatoid arthritis, are a key factor in market players capturing larger shares. These approvals introduce innovative treatments, enhancing the therapeutic landscape and indicating a continuous effort by biopharmaceutical companies to meet evolving patient needs and expand market presence.
What emerging opportunities or developments are anticipated to further shape the Canadian Anti-Rheumatic Drug Market during the forecast period?
Beyond demographic shifts and new drug approvals, the market is expected to benefit from improvements in biosimilar and innovative biologics. These advancements are anticipated to open up new business prospects within the sector, providing enhanced treatment options and driving market evolution during the forecast period.
Cite this report
Knowledge Sourcing Intelligence. (Mar 2026). Canada Anti-Rheumatic Drug Market - Strategic Insights and Forecasts (2022-2027). https://www.knowledge-sourcing.com/report/canada-anti-rheumatic-drug-market





